Replies to post #220528 on Biotech Values

[DewDiligence]

Both companies—(GILD and ABBV)—have said that US HCV pricing is stable.

[caravon]

The bottom line of any company is NOT its market share or market penetration. It is the net profit and its future growth.
ABBV shot itself in a foot with its ill-conceived HCC price war with GILD.